Arbutus Biopharma Corporation

Other

Tekmira Pharmaceuticals Corporation

Wave Life Sciences Ltd.

Alnylam Pharmaceuticals, Inc.

Regenerative Research Foundation

Mccormick and Munson Technologies, LLC

Limit Point Systems, Inc.

David Butler

Muthiah Manoharan

Kallanthottathil G Rajeev

Muthusamy Jayaraman

Jayaprakash K Nair

Laxman Eltepu

Martin A Maier

Michael E Jung

Gregory Lawrence Verdine

Naoki Iwamoto

Ivan Zlatev

Nenad Svrzikapa

Meena

Jayaprakash K Narayanannair

Daniel P McCormick

Sally Temple

Gerald L Munson

Anne Messer

Shigeo Matsuda

John H Staehlin

Rajesh Kumar Kainthan

Marco A Ciufolini

Narayanannair K Jayaprakash

Rajendra K Pandey

Kallanthottahil G Rajeev

Harold B Kirkpatrick

Mamta Kapoor

Laxmab Eltepu

Takeshi Yamada

Chang Geng Peng

Meena Meena

The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.

Chiral design

Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is (F). Also disclosed are methods of producing the cationic lipid of formula (I).

Lipid compositions

Disclosed herein are multifunctional polypeptides comprising a first domain comprising an anti-tau antigen binding domain and a second domain comprising a proteasome-targeting PEST motif, and methods for using these polypeptides in treatment of tauopathies.

Bi-functional anti-tau polypeptides and use thereof

Disclosed herein are lipid compositions comprising a cationic lipid of formula (I), a neutral lipid, a sterol and a PEG or PEG-modified lipid, wherein formula (I) is Also disclosed are methods of producing the cationic lipid of formula (I).

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures: 

Lipids and compositions for the delivery of therapeutics

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure wherein Rand Rare each independently for each occurrence optionally substituted C-Calkyl, optionally substituted C-Calkenyl, optionally substituted C-Calkynyl, optionally substituted C-Cacyl, or -linker-ligand; Ris H, optionally substituted C-Calkyl, optionally substituted C-Calkenyl, optionally substituted C-Calkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, &#x3c9;-aminoalkyls, &#x3c9;-(substituted)aminoalkyls, &#x3c9;-phosphoalkyls, &#x3c9;-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; E is O, S, N(Q), C(O), N(Q)C(O), C(O)N(Q), (Q)N(CO)O, O(CO)N(Q), S(O), NS(O)N(Q), S(O), N(Q)S(O), SS, O&#x2550;N, aryl, heteroaryl, cyclic or heterocycle; and, Q is H, alkyl, &#x3c9;-aminoalkyl, &#x3c9;-(substituted)aminoalky, &#x3c9;-phosphoalkyl or &#x3c9;-thiophosphoalkyl.

The invention provides poly(ethylene glycol)-lipid conjugates for use in drug delivery.

PEGylated lipids and their use for drug delivery

The present invention relates to chirally controlled oligonucleotides, chirally controlled oligonucleotide compositions, and the method of making and using the same. The invention specifically encompasses the identification of the source of certain problems with prior methodologies for preparing chiral oligonucleotides, including problems that prohibit preparation of fully chirally controlled compositions, particularly compositions comprising a plurality of oligonucleotide types. In some embodiments, the present invention provides chirally controlled oligonucleotide compositions. In some embodiments, the present invention provides methods of making chirally controlled oligonucleotides and chirally controlled oligonucleotide compositions.

Chiral control

The invention relates to compositions and methods for site-specific delivery of nucleic acids by combining them with targeting ligands and endosomolytic components.

Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components

Growing community of inventors

Medford, MA, United States of America

David Butler